Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) is expected to be issuing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.20). During the same period last year, the business posted ($0.40) EPS. On average, analysts expect Regulus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Regulus Therapeutics Trading Down 0.1 %
NASDAQ:RGLS traded down $0.01 during trading hours on Tuesday, hitting $7.85. The company had a trading volume of 250,390 shares, compared to its average volume of 869,887. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $8.20. The company has a 50-day moving average of $2.24 and a 200 day moving average of $1.71. The company has a market cap of $519.68 million, a P/E ratio of -7.33 and a beta of 0.49.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partnrs cut Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, May 1st. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, March 14th. Finally, Leerink Partners reiterated a "market perform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Regulus Therapeutics presently has an average rating of "Hold" and an average price target of $8.50.
View Our Latest Report on RGLS
Regulus Therapeutics Company Profile
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Featured Stories

Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.